Glucocorticoid sensitivity depends on expression levels of glucocorticoid receptors in canine neoplastic mast cells

Veterinary Immunology and Immunopathology

Volumn 144, Issue 3-4, 2011, Pages 321-328

  Matsuda, Akira ^a   Tanaka, Akane ^a   Amagai, Yosuke ^a   Ohmori, Keitaro ^a   Nishikawa, Sho ^a   Xia, Yan ^a   Karasawa, Kaoru ^a   Okamoto, Noriko ^a   Oida, Kumiko ^a   Jang, Hyosun ^a   Matsuda, Hiroshi ^a  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

Author keywords

Dog; Glucocorticoid; Glucocorticoid receptors; Mast cell tumor

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; GLYCOPROTEIN P; PREDNISOLONE; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DOG; DRUG SENSITIVITY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA CELL; MALE; MASTOCYTOMA; NONHUMAN; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR CELL LINE; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DEXAMETHASONE; DOG DISEASES; DOGS; FEMALE; GLUCOCORTICOIDS; MALE; MASTOCYTOSIS; P-GLYCOPROTEIN; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, GLUCOCORTICOID;

CANIS FAMILIARIS; RODENTIA;

EID: 81555204431     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2011.08.013     Document Type: Article

References (31)

1. Amagai Y., Tanaka A., Ohmori K., Matsuda H. Establishment of a novel high-affinity IgE receptor-positive canine mast cell line with wild-type c-kit receptors. Biochem. Biophys. Res. Commun. 2008, 366:857-861.
2. Andrade M.V., Hiragun T., Beaven M.A. Dexamethasone suppresses antigen-induced activation of phosphatidylinositol 3-kinase and downstream responses in mast cells. J. Immunol. 2004, 172:7254-7262.
3. Barnes P.J., Adcock I.M. Glucocorticoid resistance in inflammatory diseases. Lancet 2009, 373:1905-1917.
4. Behrend E.N., Kemppainen R.J. Glucocorticoid therapy. Pharmacology, indications, and complications. Vet. Clin. North Am. Small Anim. Pract. 1997, 27:187-213.
5. Farrell R.J., Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J. Endocrinol. 2003, 178:339-346.
6. Farrell R.J., Menconi M.J., Keates A.C., Kelly C.P. P-glycoprotein-170 inhibition significantly reduces cortisol and cyclosporin efflux from human intestinal epithelial cells and T lymphocytes. Aliment. Pharmacol. Ther. 2002, 16:1021-1031.
7. Finotto S., Mekori Y.A., Metcalfe D.D. Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems. J. Clin. Invest. 1997, 99:1721-1728.
8. Foroutan B., Ruf A.A., Costall B., Anderson D. An in vitro model to study chemoresistance in non-Hodgkin's lymphoma patients over-expressing mutant p53. J. Pharmacol. Toxicol. Methods 2007, 55:151-158.
9. Gu L., Zhou C., Liu H., Gao J., Li Q., Mu D., Ma Z. Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis. J. Exp. Clin. Cancer Res. 2010, 29:150.
10. Hala M., Hartmann B.L., Bock G., Geley S., Kofler R. Glucocorticoid-receptor-gene defects and resistance to glucocorticoid-induced apoptosis in human leukemic cell lines. Int. J. Cancer 1996, 68:663-668.
11. Irani A.A., Nilsson G., Ashman L.K., Schwartz L.B. Dexamethasone inhibits the development of mast cells from dispersed human fetal liver cells cultured in the presence of recombinant human stem cell factor. Immunology 1995, 84:72-78.
12. Ito K., Chung K.F., Adcock I.M. Update on glucocorticoid action and resistance. J. Allergy Clin. Immunol. 2006, 117:522-543.
13. Katoh M., Suzuyama N., Takeuchi T., Yoshitomi S., Asahi S., Yokoi T. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. J. Pharm. Sci. 2006, 95:2673-2683.
14. Mahon F.X., Hayette S., Lagarde V., Belloc F., Turcq B., Nicolini F., Belanger C., Manley P.W., Leroy C., Etienne G., Roche S., Pasquet J.M. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res. 2008, 68:9809-9816.
15. Marie J.P., Legrand O. MDR1/P-GP expression as a prognostic factor in acute leukemias. Adv. Exp. Med. Biol. 1999, 457:1-9.
16. Matsuda A., Tanaka A., Muto S., Ohmori K., Furusaka T., Jung K., Karasawa K., Okamoto N., Oida K., Itai A., Matsuda H. A novel NF-kappaB inhibitor improves glucocorticoid sensitivity of canine neoplastic lymphoid cells by up-regulating expression of glucocorticoid receptors. Res. Vet. Sci. 2010, 89:378-382.
17. McCaw D.L., Miller M.A., Ogilvie G.K., Withrow S.J., Brewer W.G., Klein M.K., Bell F.W., Anderson S.K. Response of canine mast cell tumors to treatment with oral prednisone. J. Vet. Intern. Med. 1994, 8:406-408.
18. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981, 47:207-214.
19. Ohmori K., Kawarai S., Yasuda N., Tanaka A., Matsuda H., Nishimura R., Sasaki N., Tsujimoto H., Masuda K. Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells. Vet. Immunol. Immunopathol. 2008, 126:43-53.
20. Patnaik A.K., Ehler W.J., MacEwen E.G. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet. Pathol. 1984, 21:469-474.
21. Pawlik A., Baskiewicz-Masiuk M., Machalinski B., Gawronska-Szklarz B. Involvement of P-gp in the process of apoptosis in peripheral blood mononuclear cells. Int. Immunopharmacol. 2005, 5:821-828.
22. Schmidt S., Rainer J., Ploner C., Presul E., Riml S., Kofler R. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ. 2004, 11(Suppl. 1):S45-S55.
23. Smith S.J., Piliponsky A.M., Rosenhead F., Elchalal U., Nagler A., Levi-Schaffer F. Dexamethasone inhibits maturation, cytokine production and Fc epsilon RI expression of human cord blood-derived mast cells. Clin. Exp. Allergy 2002, 32:906-913.
24. Stanclift R.M., Gilson S.D. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs. J. Am. Vet. Med. Assoc. 2008, 232:53-62.
25. Strasser-Wozak E.M., Hattmannstorfer R., Hala M., Hartmann B.L., Fiegl M., Geley S., Kofler R. Splice site mutation in the glucocorticoid receptor gene causes resistance to glucocorticoid-induced apoptosis in a human acute leukemic cell line. Cancer Res. 1995, 55:348-353.
26. Takahashi T., Kadosawa T., Nagase M., Matsunaga S., Mochizuki M., Nishimura R., Sasaki N. Visceral mast cell tumors in dogs: 10 cases (1982-1997). J. Am. Vet. Med. Assoc. 2000, 216:222-226.
27. Takahashi T., Kadosawa T., Nagase M., Mochizuki M., Matsunaga S., Nishimura R., Sasaki N. Inhibitory effects of glucocorticoids on proliferation of canine mast cell tumor. J. Vet. Med. Sci. 1997, 59:995-1001.
28. Tanaka A., Konno M., Muto S., Kambe N., Morii E., Nakahata T., Itai A., Matsuda H. A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 2005, 105:2324-2331.
29. van der Kolk D.M., de Vries E.G., Muller M., Vellenga E. The role of drug efflux pumps in acute myeloid leukemia. Leuk. Lymphoma 2002, 43:685-701.
30. Werner S., Bronnegard M. Molecular basis of glucocorticoid-resistant syndromes. Steroids 1996, 61:216-221.
31. Yoshikawa H., Nakajima Y., Tasaka K. Glucocorticoid suppresses autocrine survival of mast cells by inhibiting IL-4 production and ICAM-1 expression. J. Immunol. 1999, 162:6162-6170.